U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Severe hemophilia B

MedGen UID:
1826004
•Concept ID:
C5679576
•
Disease or Syndrome
Synonyms: Severe congenital F9 deficiency; Severe congenital factor IX deficiency; severe factor IX deficiency; severe haemophilia type B; severe hemophilia B; severe hemophilia type B
Modes of inheritance:
X-linked recessive inheritance
MedGen UID:
375779
•Concept ID:
C1845977
•
Finding
Source: Orphanet
A mode of inheritance that is observed for recessive traits related to a gene encoded on the X chromosome. In the context of medical genetics, X-linked recessive disorders manifest in males (who have one copy of the X chromosome and are thus hemizygotes), but generally not in female heterozygotes who have one mutant and one normal allele.
See: This record
X-linked recessive inheritance (Orphanet)
 
Monarch Initiative: MONDO:0015715
Orphanet: ORPHA169793

Definition

A severe form of hemophilia B characterized by a large deficiency of factor IX (biological activity <1 IU/dL) leading to frequent spontaneous hemorrhage and abnormal bleeding as a result of minor injuries or following trauma, surgery or tooth extraction. It primarily affects males but may also be observed in female carriers of disease-causing mutations. [from ORDO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVSevere hemophilia B

Professional guidelines

PubMed

Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G, Coppens M, Pipe SW
Expert Rev Hematol 2023 Jul-Dec;16(12):919-932. Epub 2023 Dec 18 doi: 10.1080/17474086.2023.2276206. PMID: 37882214
Gene Therapy Approaches for the Treatment of Hemophilia B.
Soroka AB, Feoktistova SG, Mityaeva ON, Volchkov PY
Int J Mol Sci 2023 Jun 28;24(13) doi: 10.3390/ijms241310766. PMID: 37445943Free PMC Article
Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China.
Zhou T, Wang S, Zhang Y, Wu R, Li H
Pediatr Blood Cancer 2023 Jun;70(6):e30264. Epub 2023 Feb 23 doi: 10.1002/pbc.30264. PMID: 36815588

Recent clinical studies

Etiology

Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G, Coppens M, Pipe SW
Expert Rev Hematol 2023 Jul-Dec;16(12):919-932. Epub 2023 Dec 18 doi: 10.1080/17474086.2023.2276206. PMID: 37882214
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, Dolan G, Reiss U, Phillips M, Riddell A, Peralta MR, Quaye M, Patch DW, Tuddenham E, Dane A, Watissée M, Long A, Nathwani A
N Engl J Med 2022 Jul 21;387(3):237-247. doi: 10.1056/NEJMoa2119913. PMID: 35857660
Molecular analysis of severe hemophilia B in Indian families: Identification of mutational hotspot and novel variants.
Agrawal N, Kumar R, Masih S, Srivastava P, Singh P, Jaiswal SK, Moirangthem A, Saxena D, Phadke SR, Mandal K
Int J Lab Hematol 2022 Feb;44(1):186-192. Epub 2021 Sep 29 doi: 10.1111/ijlh.13715. PMID: 34590426
Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM
N Engl J Med 2014 Nov 20;371(21):1994-2004. doi: 10.1056/NEJMoa1407309. PMID: 25409372Free PMC Article
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM
N Engl J Med 2011 Dec 22;365(25):2357-65. Epub 2011 Dec 10 doi: 10.1056/NEJMoa1108046. PMID: 22149959Free PMC Article

Diagnosis

The Molecular Basis of FIX Deficiency in Hemophilia B.
Shen G, Gao M, Cao Q, Li W
Int J Mol Sci 2022 Mar 2;23(5) doi: 10.3390/ijms23052762. PMID: 35269902Free PMC Article
Invisible bleeds: Lived experiences and barriers to care for men with hemophilia.
Arya S, Siad FM, Wilton P, Page D, Boma-Fischer L, Floros G, Winikoff R, Teitel J, Sholzberg M
J Thromb Haemost 2022 Feb;20(2):296-306. Epub 2021 Nov 8 doi: 10.1111/jth.15570. PMID: 34689399
Molecular analysis of severe hemophilia B in Indian families: Identification of mutational hotspot and novel variants.
Agrawal N, Kumar R, Masih S, Srivastava P, Singh P, Jaiswal SK, Moirangthem A, Saxena D, Phadke SR, Mandal K
Int J Lab Hematol 2022 Feb;44(1):186-192. Epub 2021 Sep 29 doi: 10.1111/ijlh.13715. PMID: 34590426
The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective.
Bolous NS, Chen Y, Wang H, Davidoff AM, Devidas M, Jacobs TW, Meagher MM, Nathwani AC, Neufeld EJ, Piras BA, Rodriguez-Galindo C, Reiss UM, Bhakta N
Blood 2021 Nov 4;138(18):1677-1690. doi: 10.1182/blood.2021010864. PMID: 33895800
Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.
Atsou S, Furlan F, Duchemin J, Ellouze S, Sourdeau É, Launois A, Roussel-Robert V, Stieltjes N, Combe S, Fontenay M, Curis E, Jourdi G
Eur J Pharmacol 2021 Jan 15;891:173764. Epub 2020 Nov 27 doi: 10.1016/j.ejphar.2020.173764. PMID: 33249076

Therapy

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE
N Engl J Med 2023 Feb 23;388(8):706-718. doi: 10.1056/NEJMoa2211644. PMID: 36812434
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, Dolan G, Reiss U, Phillips M, Riddell A, Peralta MR, Quaye M, Patch DW, Tuddenham E, Dane A, Watissée M, Long A, Nathwani A
N Engl J Med 2022 Jul 21;387(3):237-247. doi: 10.1056/NEJMoa2119913. PMID: 35857660
Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues.
Leebeek FWG, Miesbach W
Blood 2021 Sep 16;138(11):923-931. doi: 10.1182/blood.2019003777. PMID: 34232980
Gene therapy for hemophilia.
Nathwani AC
Hematology Am Soc Hematol Educ Program 2019 Dec 6;2019(1):1-8. doi: 10.1182/hematology.2019000007. PMID: 31808868Free PMC Article
Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM
N Engl J Med 2014 Nov 20;371(21):1994-2004. doi: 10.1056/NEJMoa1407309. PMID: 25409372Free PMC Article

Prognosis

Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J, Kim H, Sivamurthy K, Monahan PE, Fries M
Curr Med Res Opin 2023 Feb;39(2):227-237. Epub 2022 Oct 25 doi: 10.1080/03007995.2022.2133492. PMID: 36285399
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, Dolan G, Reiss U, Phillips M, Riddell A, Peralta MR, Quaye M, Patch DW, Tuddenham E, Dane A, Watissée M, Long A, Nathwani A
N Engl J Med 2022 Jul 21;387(3):237-247. doi: 10.1056/NEJMoa2119913. PMID: 35857660
Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.
Atsou S, Furlan F, Duchemin J, Ellouze S, Sourdeau É, Launois A, Roussel-Robert V, Stieltjes N, Combe S, Fontenay M, Curis E, Jourdi G
Eur J Pharmacol 2021 Jan 15;891:173764. Epub 2020 Nov 27 doi: 10.1016/j.ejphar.2020.173764. PMID: 33249076
Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM
N Engl J Med 2014 Nov 20;371(21):1994-2004. doi: 10.1056/NEJMoa1407309. PMID: 25409372Free PMC Article
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM
N Engl J Med 2011 Dec 22;365(25):2357-65. Epub 2011 Dec 10 doi: 10.1056/NEJMoa1108046. PMID: 22149959Free PMC Article

Clinical prediction guides

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE
N Engl J Med 2023 Feb 23;388(8):706-718. doi: 10.1056/NEJMoa2211644. PMID: 36812434
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, Dolan G, Reiss U, Phillips M, Riddell A, Peralta MR, Quaye M, Patch DW, Tuddenham E, Dane A, Watissée M, Long A, Nathwani A
N Engl J Med 2022 Jul 21;387(3):237-247. doi: 10.1056/NEJMoa2119913. PMID: 35857660
Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries.
Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, Germini F; Data and Demographics Committee of the World Federation of Hemophilia
Ann Intern Med 2019 Oct 15;171(8):540-546. Epub 2019 Sep 10 doi: 10.7326/M19-1208. PMID: 31499529
Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM
N Engl J Med 2014 Nov 20;371(21):1994-2004. doi: 10.1056/NEJMoa1407309. PMID: 25409372Free PMC Article
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM
N Engl J Med 2011 Dec 22;365(25):2357-65. Epub 2011 Dec 10 doi: 10.1056/NEJMoa1108046. PMID: 22149959Free PMC Article

Recent systematic reviews

Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
Iorio A, Krishnan S, Myrén KJ, Lethagen S, McCormick N, Yermakov S, Karner P
J Med Econ 2017 Apr;20(4):337-344. Epub 2016 Dec 21 doi: 10.1080/13696998.2016.1265973. PMID: 27885871
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders.
Tagariello G, Iorio A, Santagostino E, Morfini M, Bisson R, Innocenti M, Mancuso ME, Mazzucconi MG, Pasta GL, Radossi P, Rodorigo G, Santoro C, Sartori R, Scaraggi A, Solimeno LP, Mannucci PM; Italian Association Hemophilia Centre (AICE)
Blood 2009 Jul 23;114(4):779-84. Epub 2009 Apr 8 doi: 10.1182/blood-2009-01-195313. PMID: 19357395

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Reviews

    Related information

    • GTR
      Related information in GTR
    • GTR(Clinical)
      Clinical tests in GTR
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...